Targeting BRAF for patients with melanoma

por Arkenau, H-T, Kefford, R, Long, G V
Publicado em 2011

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA)

por Uccello, M., Moschetta, M., Mak, G., Alam, T., Henriquez, C. Murias, Arkenau, H.-T.
Publicado no Curr Oncol (2018)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

por Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S
Publicado em 2008

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience

por Olmos, D, Arkenau, H-T, Ang, J E, de Bono, J S, Judson, I, Kaye, S B
Publicado em 2008

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

por Nehls, O, Klump, B, Arkenau, H T, Hass, H G, Greschniok, A, Gregor, M, Porschen, R
Publicado em 2002

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado em 2009

Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapo...

por Nehls, O, Okech, T, Hsieh, C-J, Enzinger, T, Sarbia, M, Borchard, F, Gruenagel, H-H, Gaco, V, Hass, H G, Arkenau, H T, Hartmann, J T, Porschen, R, Gregor, M, Klump, B
Publicado em 2007

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

por Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Publicado no ESMO Open (2021)

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

por Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Publicado em 2012

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escal...

por Molife, L R, Fong, P C, Paccagnella, L, Reid, A H M, Shaw, H M, Vidal, L, Arkenau, H-T, Karavasilis, V, Yap, T A, Olmos, D, Spicer, J, Postel-Vinay, S, Yin, D, Lipton, A, Demers, L, Leitzel, K, Gualberto, A, de Bono, J S
Publicado em 2010

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

por Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.
Publicado em 2012

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

por Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E. B., Hui, R., Arkenau, H.-T., Gubens, M. A., Hellmann, M. D., Dong, D., Li, C., Mayawala, K., Freshwater, T., Ahamadi, M., Stone, J., Lubiniecki, G. M., Zhang, J., Im, E., De Alwis, D. P., Kondic, A. G., Fløtten, Ø.
Publicado no Ann Oncol (2016)